Verrica Pharmaceuticals I... (VRCA)
0.67
0.02 (3.22%)
At close: Mar 03, 2025, 12:40 PM
Verrica Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
| Revenue | 5.12M | 9.03M | 12M | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 746K | 725K | 472K | 229K | 257.2K | 20.29K | n/a | n/a |
| Gross Profit | 4.38M | 8.31M | 11.53M | -229K | -257.2K | -20.29K | n/a | n/a |
| Operating Income | -65.76M | -21.3M | -30.91M | -40.18M | -30.08M | -21.88M | -4.46M | -1.91M |
| Interest Income | 2.74M | 476K | 123K | 521K | 1.88M | 1.23M | n/a | n/a |
| Pretax Income | -67M | -24.49M | -35.08M | -42.69M | -28.21M | -20.65M | -4.46M | -1.91M |
| Net Income | -67M | -27.68M | -38.9M | -45.5M | -27.95M | -20.65M | -4.46M | -1.91M |
| Selling & General & Admin | 47.3M | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727K | 204K |
| Research & Development | 20.3M | 12.2M | 15.93M | 15.67M | 15.44M | 12.83M | 3.73M | 1.71M |
| Other Expenses | 2.54M | -58K | n/a | -1K | 1.87M | -1K | n/a | n/a |
| Operating Expenses | 70.14M | 29.6M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Interest Expense | 3.96M | 2.17M | 4.29M | 3.03M | n/a | n/a | 2K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 70.88M | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Income Tax | n/a | 3.19M | 3.82M | 2.8M | -257K | 1.23M | -4.46M | -1.91M |
| Shares Outstanding (Basic) | 45.34M | 34.16M | 27.04M | 25M | 24.9M | 14.66M | 19.95M | 19.95M |
| Shares Outstanding (Diluted) | 45.34M | 34.16M | 27.04M | 25M | 24.9M | 14.66M | 19.95M | 19.95M |
| EPS (Basic) | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.1 |
| EPS (Diluted) | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.1 |
| EBITDA | -62.2M | -21.6M | -30.31M | -39.43M | -30.08M | -20.63M | -4.46M | -1.91M |
| Depreciation & Amortization | 836K | 718K | 472K | 229K | 257.2K | 20.29K | 4.46M | 1.91M |